|Core Patent for NWCI's 3-D ECG platform technology|
|Thursday, 25 February 2010 10:24|
This is an important part of the developing story for NWCI, which we have been following since mid January. In addition, for those of you who missed the company's most recent 10K filing, there appears to be clear validation of the rumors we reported. regarding a buy-out or partnership which may not be too far in the horizon.
In that filing, there is a paragraph makes mention of exploring strategic partnerships that would require "equity investments" on behalf of the partner.
This morning, the cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG), announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering technology relating to NewCardio's Cardio3KG solution (formerly VisualECG or Visual3Dx). This represents the core patent for NewCardio's anticipated emergency/urgent care solution, Cardio3KG.
The Cardio3KG solution is comprised of a set of algorithms and tools that provide a comprehensive method to assess cardiac electrical activity in time and space, and to extract additional 3-dimensional information from standard 12-lead ECG signals. This may enable Cardio3KG to assess potentially fatal diseases and conditions, including acute coronary syndrome, with greater speed and accuracy than possible by standard ECG.
When issued, together with US patent 7,266,408, this will be NewCardio's second U.S. patent covering broad aspects of the Company's 3-D ECG platform technology and, particularly, specifics of Cardio3KG, the first solution targeted to take full advantage of this intellectual property.
"This action by the USPTO reinforces our continuing investment in and commitment to our novel cardiovascular diagnostic platform technology, which provides 3-D analysis of the heart's electrical activity," stated NewCardio's CEO, Branislav Vajdic, PhD. "We believe the Cardio3KG solution will substantially improve the accuracy and timeliness of response and diagnosis for patients arriving at emergency departments with heart attack symptoms and related conditions. NewCardio's Cardio3KG will enable doctors to diagnose acute coronary syndromes more quickly and accurately than with traditional methods, possibly saving thousands of lives annually and reducing costs associated with unnecessary hospital admissions. We also believe Cardio3KG, along with QTinnoâ¢ and CardioBipâ¢, represent important steps forward in validating our 3-D ECG platform's ability to improve cardiac diagnosis, clinical outcomes, and drug safety. Â We are pleased that patent offices in both the US and Europe are acknowledging our proprietary claims to our core technologies."
We continue to stand by our story that this is a company headed big places- including an upgrade to the NASDQ. The company's three core technologies are set to capture huge market shares of both existing and new markets.
(On a side note, we are still chasing the CBLI story that we promised to bring you today. Look for that in this space by Monday as there are some intriguing rumors and chatter that have implications for the future price of the stock.)
Disclosure: Still long NWCI